SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity
NCT05764811
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Fatty Liver Disease
Interventions
DRUG:
Canagliflozin 100mg
Sponsor
National Cheng-Kung University Hospital